Results Of Phase I Testing Of Lmb2

LMB-2 was administered at 2-63 ^g/kg q.o.d. X 3 to a total of 35 patients with chemotherapy-resistant hema-tologic malignancies, including 11 with Hodgkin's disease, 6 with B-cell NHL, 8 with CLL, 4 with HCL, 3 with peripheral T-cell lymphoma (PTCL), 1 with cutaneous T-cell lymphoma (CTCL), and 2 with ATL.68 DLT was observed at 63 ^g/kg i.v. q.o.d. X3, the dose at which one patient had grade 4 transaminase elevations and another had nausea, vomiting, and diarrhea followed by a transient cardiomyopathy.

Table 33.2 LMB-2 in patients with HCL
0 0

Post a comment